Momenta Pharmaceuticals, Inc. (MNTA) SVP Sells $29,776.00 in Stock

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) SVP Bruce Leicher sold 1,861 shares of the firm’s stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $16.00, for a total transaction of $29,776.00. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Bruce Leicher also recently made the following trade(s):

  • On Tuesday, November 21st, Bruce Leicher sold 803 shares of Momenta Pharmaceuticals stock. The shares were sold at an average price of $13.15, for a total transaction of $10,559.45.

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) traded up $0.05 during trading on Monday, reaching $16.30. 571,269 shares of the company were exchanged, compared to its average volume of 921,225. Momenta Pharmaceuticals, Inc. has a 1 year low of $11.85 and a 1 year high of $19.46. The firm has a market cap of $1,250.00, a PE ratio of -20.38 and a beta of 1.80.

A number of institutional investors have recently added to or reduced their stakes in MNTA. Renaissance Technologies LLC grew its stake in Momenta Pharmaceuticals by 186.4% in the 2nd quarter. Renaissance Technologies LLC now owns 797,400 shares of the biotechnology company’s stock valued at $13,476,000 after acquiring an additional 519,000 shares during the period. Vanguard Group Inc. grew its stake in Momenta Pharmaceuticals by 4.9% in the 2nd quarter. Vanguard Group Inc. now owns 6,243,767 shares of the biotechnology company’s stock valued at $105,519,000 after acquiring an additional 290,090 shares during the period. State Street Corp grew its stake in Momenta Pharmaceuticals by 8.1% in the 2nd quarter. State Street Corp now owns 2,653,427 shares of the biotechnology company’s stock valued at $44,842,000 after acquiring an additional 197,978 shares during the period. Fisher Asset Management LLC acquired a new stake in Momenta Pharmaceuticals in the 3rd quarter valued at $1,823,000. Finally, Northern Trust Corp grew its stake in Momenta Pharmaceuticals by 12.1% in the 2nd quarter. Northern Trust Corp now owns 904,238 shares of the biotechnology company’s stock valued at $15,283,000 after acquiring an additional 97,893 shares during the period. 93.01% of the stock is currently owned by hedge funds and other institutional investors.

Several equities analysts have recently weighed in on MNTA shares. Cowen set a $15.00 target price on shares of Momenta Pharmaceuticals and gave the company a “hold” rating in a report on Wednesday, November 1st. Zacks Investment Research lowered shares of Momenta Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, December 4th. BidaskClub lowered shares of Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, December 7th. Finally, Stifel Nicolaus reaffirmed a “hold” rating and set a $18.00 target price on shares of Momenta Pharmaceuticals in a report on Tuesday, January 30th. Two equities research analysts have rated the stock with a sell rating and ten have given a hold rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $15.30.

ILLEGAL ACTIVITY NOTICE: This piece was first published by American Banking News and is the property of of American Banking News. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this piece can be read at https://www.americanbankingnews.com/2018/02/12/momenta-pharmaceuticals-inc-mnta-svp-sells-29776-00-in-stock.html.

Momenta Pharmaceuticals Company Profile

Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).

Insider Buying and Selling by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply